• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by IRIDEX Corporation (Amendment)

    9/1/21 4:52:44 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $IRIX alert in real time by email
    SC 13D/A 1 sc_13da_iterimcorporation.htm
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    SCHEDULE 13D/A
    (Rule 13d-101)

    (Amendment No. 7)

    Under the Securities Exchange Act of 1934

    Iridex Corporation
    _____________________________________________________________________________
    (NAME OF ISSUER)

    Shares of Common Stock, $0.01 par value
    _____________________________________________________________________________
    (Title of Class of Securities)

    462684101
    _____________________________________________________________________________
    (CUSIP NUMBER)

    Paragon Associates and Paragon Associates II Joint Venture
    500 Crescent Court, Suite 260
    Dallas, Texas 75201
    Tel. No.: (214) 871-3700
    _____________________________________________________________________________
    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

    - with copies to -
    Eliot D. Raffkind
    Akin, Gump, Strauss, Hauer & Feld, L.L.P.
    2300 N Field Street, Suite 1800
    Dallas, Texas 75201
    (214) 969-2800

    August 30, 2021
    _____________________________________________________________________________
    (Date of event which requires filing of this statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g) check the following box [  ]

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Act”), or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.



    CUSIP NO. 462684101
     13D/A
     

    1
    NAME OF REPORTING PERSONS
     
    Paragon Associates and Paragon Associates II Joint Venture
     2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*               (a) □ (b) □


    3
    SEC USE ONLY
     
     
    4
    SOURCE OF FUNDS*
     
    WC
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)               ☐

     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Texas
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7
    SOLE VOTING POWER
     
    789,818
    8
    SHARED VOTING POWER

    0
    9
    SOLE DISPOSITIVE POWER

    789,818
    10
    SHARED DISPOSITIVE POWER

    0
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    789,818
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)                              ☐
    EXCLUDES CERTAIN SHARES*

    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    4.99%**
    14
    TYPE OF REPORTING PERSON*

    OO
              *SEE INSTRUCTIONS BEFORE FILLING OUT
              **SEE ITEM 5(a).




    CUSIP NO. 462684101
     13D/A
     

    1
    NAME OF REPORTING PERSONS
     
    Paragon JV Partners, LLC
     2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*               (a) □ (b) □


    3
    SEC USE ONLY
     
     
    4
    SOURCE OF FUNDS*
     
    WC
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)               ☐

     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Texas
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7
    SOLE VOTING POWER
     
    789,818
    8
    SHARED VOTING POWER

    0
    9
    SOLE DISPOSITIVE POWER

    789,818
    10
    SHARED DISPOSITIVE POWER

    0
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    789,818
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)                              ☐

    EXCLUDES CERTAIN SHARES*
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    4.99%**
    14
    TYPE OF REPORTING PERSON*

    OO
              *SEE INSTRUCTIONS BEFORE FILLING OUT
              **SEE ITEM 5(a).




    CUSIP NO. 462684101
     13D/A
     

    1
    NAME OF REPORTING PERSONS
     
    Bradbury Dyer III
     2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*               (a) □ (b) □


    3
    SEC USE ONLY
     
     
    4
    SOURCE OF FUNDS*
     
    WC
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)               ☐

     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7
    SOLE VOTING POWER
     
    789,818
    8
    SHARED VOTING POWER

    0
    9
    SOLE DISPOSITIVE POWER

    789,818
    10
    SHARED DISPOSITIVE POWER

    0
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    789,818
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)                              ☐
    EXCLUDES CERTAIN SHARES*

    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    4.99%**
    14
    TYPE OF REPORTING PERSON*

    IN
              *SEE INSTRUCTIONS BEFORE FILLING OUT
              **SEE ITEM 5(a).





    AMENDMENT NO. 7 TO SCHEDULE 13D

                 This Amendment No. 7 to Schedule 13D (this “Amendment”) is being filed on behalf of (i) Paragon Associates and Paragon Associates II Joint Venture, a joint venture (“Paragon JV”) formed by Paragon Associates, Ltd., a Texas limited partnership (“Paragon”), Paragon Associates II, Ltd., a Texas limited partnership (“Paragon II”), and Paragon Associates III, Ltd. a Texas limited partnership (“Paragon III”), (ii) Paragon JV Partners, LLC, a Texas limited liability company (“Paragon GP”), and (iii) Bradbury Dyer III (“Mr. Dyer”, and collectively with Paragon JV and Paragon GP, the “Reporting Persons”).  This Amendment further modifies the original Schedule 13D filed with the Securities and Exchange Commission on January 8, 2009 (the “Original 13D), as amended by the Amendment No. 1 to Schedule 13D filed with the Securities and Exchange Commission on February 10, 2009, as amended by the Amendment No. 2 to Schedule 13D filed with the Securities and Exchange Commission on November 4, 2013, as amended by the Amendment No. 3 to Schedule 13D filed with the Securities and Exchange Commission on July 27, 2015, as amended by the Amendment No. 4 to Schedule 13D filed with the Securities and Exchange Commission on August 24, 2015, as amended by the Amendment No. 5 to Schedule 13D filed with the Securities and Exchange Commission on April 13, 2021, as amended by the Amendment No. 6 to Schedule 13D filed with the Securities and Exchange Commission on July 2, 2021 (the Original 13D, as so amended, the “Schedule 13D”), relating to shares of common stock, $0.01 par value (the “Common Stock”) of Iridex Corporation, a Delaware corporation (the “Issuer”). As set forth below, as a result of the transactions described herein, on August 31, 2021 each of the Reporting Persons ceased to be the beneficial owner of more than five percent of the outstanding shares of Common Stock. The filing of this Amendment represents the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Persons.

    This Amendment relates to Common Stock sold by Mr. Dyer for the account of Paragon JV on behalf of Paragon, Paragon II and Paragon III.  Paragon GP serves as the general partner of each of Paragon, Paragon II and Paragon III and as the investment advisor of Paragon JV and may direct the vote and disposition of the 789,818 shares of Common Stock held by Paragon JV.  As the sole and managing member of Paragon GP, Mr. Dyer may direct Paragon GP to direct, and, as the authorized agent to Paragon JV, may direct, the vote and disposition of the 789,818 shares of Common Stock held by Paragon JV.

    Item 5.
    Interest in Securities of the Issuer
                       
    Item 5 of the Schedule 13D is hereby amended and restated in its entirety to read as follows:  

     
    (a)    As of September 1, 2021, Paragon JV, by virtue of carrying out the purposes of Paragon, Paragon II and Paragon III per the joint venture agreement of Paragon JV, a copy of which was filed as Exhibit 2 to the Original 13D and is incorporated herein by reference, as subsequently amended by the First Amendment thereto, a copy of which was filed as Exhibit 3 to the Original 13D, beneficially owns 789,818 shares of Common Stock, which represents 4.99% of the Issuer’s outstanding shares of Common Stock.
     
     
     
           The percentage of ownership of the Reporting Persons, as reported in this Schedule 13D was calculated by dividing (i) 789,818 shares of Common Stock owned by Paragon JV, by (ii) 15,832,258 shares of Common Stock outstanding as of August 5, 2021 based upon the Form 10-Q filed with the Securities and Exchange Commission on August 12, 2021.
     
     
     
           Paragon GP does not have direct beneficial ownership of the 789,818 shares of the Issuer’s Common Stock; however, Paragon GP, as the general partner of each of Paragon, Paragon II and Paragon III, may be deemed, for purposes of determining beneficial ownership pursuant to Rule 13d-3, to have indirect beneficial ownership of such shares.
     
     
     
           Mr. Dyer does not have direct beneficial ownership of the 789,818 shares of the Issuer’s Common Stock; however, Mr. Dyer, as sole and managing member of Paragon GP, and as agent for Paragon JV, may be deemed, for purposes of determining beneficial ownership pursuant to Rule 13d-3, to have indirect beneficial ownership of such shares.
     
     

    (b)    Paragon JV has the power to vote and dispose of the 789,818 shares of Common Stock it holds; Paragon GP, as the general partner of each of Paragon, Paragon II and Paragon III, has the power to vote and dispose of the 789,818 shares of Common Stock held by Paragon JV; and Mr. Dyer, as the sole and managing member of Paragon JV and the authorized agent of Paragon JV, has the power to vote and dispose of the 789,818 shares of Common Stock held by Paragon JV.
     
     

    (c)    Except as reported in the Schedule 13D, Annex A attached hereto lists all transactions in the Common Stock during the past sixty (60) days by the Reporting Persons.  The transactions in the Common Stock were effected in the open market.
     
     

    (d)    Not Applicable.
     
     

    (e)    As a result of the transactions described herein, on August 31, 2021 each of the Reporting Persons ceased to be the beneficial owner of more than five percent of the outstanding shares of Common Stock. The filing of this Amendment represents the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Persons.






    SIGNATURES


    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.


    Date: September 1, 2021
    PARAGON ASSOCIATES AND PARAGON ASSOCIATES II JOINT VENTURE
       
     
    By: /s/ Bradbury Dyer III
     
    Name: Bradbury Dyer III
     
    Title: Authorized Agent
       
       
      PARAGON JV PARTNERS, LLC
       
     
    By: /s/ Bradbury Dyer III
      Name: Bradbury Dyer III
     
    Title: Sole and Managing Member
       
      BRADBURY DYER III
       
     
    By: /s/ Bradbury Dyer III


    ANNEX A

    Except as previously disclosed in this Schedule 13D, as amended, the following table sets forth all transactions by the Reporting Persons or on behalf of the Reporting Persons with respect to securities of the Issuer effected in the last 60 days, inclusive of any transactions effected through 4:00 p.m., New York City time, on September 1, 2021. All such transactions were sales of securities of the Issuer effected in the open market, and the table excludes commissions paid in per share prices.

    Trade
     
    Buy /
    Shares of
    Price per Share
    Date
    Security
    (Sell)
    Common Stock
    (US$)
    ----------
    -------------------------
    ----
    --------------
    --------------
    7/20/2021
    Iridex Corp IRIX
    (Sell)
                        25,000
     $ 6.6298 (1)
    7/21/2021
    Iridex Corp IRIX
    (Sell)
    12,467
    $ 6.6478
    7/22/2021
    Iridex Corp IRIX
    (Sell)
    25,000
    $6.6457 (2)
    8/2/2021
    Iridex Corp IRIX
    (Sell)
                        12,065
     $ 6.6303 (3)
    8/3/2021
    Iridex Corp IRIX
    (Sell)
    12,935
    $ 6.5936 (4)
    8/4/2021
    Iridex Corp IRIX
    (Sell)
    18,668
    $6.6217 (5)
    8/5/2021
    Iridex Corp IRIX
    (Sell)
                        17,051
     $ 6.6634 (6)
    8/6/2021
    Iridex Corp IRIX
    (Sell)
    4,745
    $ 6.5865 (7)
    8/9/2021
    Iridex Corp IRIX
    (Sell)
                         8,150
     $ 6.5921 (8)
    8/10/2021
    Iridex Corp IRIX
    (Sell)
    4,142
    $ 6.6481 (9)
    8/12/2021
    Iridex Corp IRIX
    (Sell)
    10,863
    $6.6215 (10)
    8/24/2021
    Iridex Corp IRIX
    (Sell)
                         3,445
     $ 7.8112 (11)
    8/25/2021
    Iridex Corp IRIX
    (Sell)
    400
    $ 7.815
    8/26/2021
    Iridex Corp IRIX
    (Sell)
    3,100
    $7.5367
    8/30/2021
    Iridex Corp IRIX
    (Sell)
                        12,825
     $ 7.7862 (12)
    8/31/2021
    Iridex Corp IRIX
    (Sell)
    20,000
    $ 7.6911 (13)

    (1)
    The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.60 to $6.6706, inclusive. The reporting persons undertake to provide to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3). (4), (5), (6), (7), (8), (9), (10), (11), (12), and (13).
    (2)
    The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.62 to $6.65, inclusive.
    (3)
    The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.6101 to $6.7279, inclusive.
    (4)
    The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.58 to $6.6053, inclusive.
    (5)
    The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.59 to $6.64, inclusive.
    (6)
    The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.58 to $6.7157, inclusive.
    (7)
    The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.58 to $6.5911, inclusive.
    (8)
    The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.5875 to $6.6101, inclusive.
    (9)
    The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.60 to $6.685, inclusive.
    (10)
    The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.60 to $6.6364, inclusive.
    (11)
    The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.80 to $7.8606, inclusive.
    (12)
    The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.75 to $7.8443, inclusive.
    (13)
    The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.61 to $7.75, inclusive.

    Get the next $IRIX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IRIX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IRIX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vicarious Surgical Announces Election of New Directors

      Vicarious Surgical Inc. (NYSE:RBOT, RBOT WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the election of Fuad Ahmad and Joseph Doherty to the Vicarious Surgical Board of Directors at the Company's 2025 Annual Meeting of Stockholders held on June 27, 2025. The Company also announced the departure of Ric Fulop from the Vicarious Surgical Board of Directors effective as of the Annual Meeting. "On behalf of the board, I am thrilled to welcome Fuad and Joseph to the Vicarious team. Their decades of experience and insight will be instrumental as we continue our advance towards our clinical trial and th

      6/30/25 6:45:00 AM ET
      $GSAT
      $IRIX
      $JNJ
      $MITK
      Telecommunications Equipment
      Consumer Discretionary
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex Announces First Patient Enrolled in an Independent Landmark Investigator-Led UK Study Evaluating MicroPulse® Technology as an Adjunct to anti-VEGF Therapy for Diabetic Macular Edema

      MOUNTAIN VIEW, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, announced today that the first patient has been successfully enrolled in the independent, investigator-led DAME Trial to evaluate the clinical efficacy, safety, cost-effectiveness, and patient acceptability of adding subthreshold MicroPulse treatments to anti-vascular endothelial growth factor (anti-VEGF) therapy in patients presenting with severe diabetic macular edema (DME). Led by Principal Investigator Professor Noemi Lois at Que

      6/24/25 7:00:00 AM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex Reports First Quarter 2025 Financial Results

      MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended March 29, 2025. First Quarter 2025 Financial Highlights Total revenue was $11.9 million, compared to $11.8 million in the first quarter of 2024Cyclo G6® product family revenue was $3.2 million, an increase of 8% year-over-year, compared to $3.0 million in the prior year quarter Sold 13,900 Cyclo G6 probes compared to 13,300 in the prior year quarterSold 24 Cyclo G

      5/13/25 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital reiterated coverage on Iridex with a new price target

      Roth Capital reiterated coverage of Iridex with a rating of Buy and set a new price target of $11.00 from $9.00 previously

      5/12/21 11:32:01 AM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Roth Capital reiterated coverage on IRIDEX with a new price target

      Roth Capital reiterated coverage of IRIDEX with a rating of Buy and set a new price target of $9.00 from $6.00 previously

      3/9/21 8:09:06 AM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Roth Capital reiterated coverage on Iridex with a new price target

      Roth Capital reiterated coverage of Iridex with a rating of Buy and set a new price target of $9.00 from $6.00 previously

      3/3/21 12:29:03 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by Director Shuda Scott

      4/A - IRIDEX CORP (0001006045) (Issuer)

      6/24/25 8:27:45 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form 4 filed by Director Huss Beverly A

      4/A - IRIDEX CORP (0001006045) (Issuer)

      6/24/25 8:23:56 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Director Chen Yu-Hao

      4 - IRIDEX CORP (0001006045) (Issuer)

      6/24/25 8:21:29 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Moore William M bought $19,372 worth of shares (20,000 units at $0.97), increasing direct ownership by 12% to 188,650 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      6/16/25 1:44:46 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • President and CEO Mercer Patrick bought $240 worth of shares (250 units at $0.96), increasing direct ownership by 0.06% to 386,730 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      6/13/25 2:43:38 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Moore William M bought $29,121 worth of shares (30,000 units at $0.97), increasing direct ownership by 22% to 168,650 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      6/13/25 1:28:06 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    SEC Filings

    See more
    • SEC Form S-8 filed by IRIDEX Corporation

      S-8 - IRIDEX CORP (0001006045) (Filer)

      6/13/25 5:12:55 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • IRIDEX Corporation filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - IRIDEX CORP (0001006045) (Filer)

      6/13/25 4:38:59 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form DEFA14A filed by IRIDEX Corporation

      DEFA14A - IRIDEX CORP (0001006045) (Filer)

      6/2/25 4:06:37 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by IRIDEX Corporation

      SC 13D - IRIDEX CORP (0001006045) (Subject)

      11/23/22 4:57:01 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13D filed by IRIDEX Corporation

      SC 13D - IRIDEX CORP (0001006045) (Subject)

      9/20/22 2:06:59 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by IRIDEX Corporation (Amendment)

      SC 13G/A - IRIDEX CORP (0001006045) (Subject)

      2/10/22 8:17:17 AM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care